Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Ferring Pharmaceuticals clinical trials
The registry lists 254 studies whose lead sponsor is Ferring Pharmaceuticals or one of 1 company grouped under it. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 21, 2026.
Keep track of what changes. Save the Ferring Pharmaceuticals studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Ferring Pharmaceuticals.
- Ferring Pharmaceuticals249 studiesSame company
Something wrong?
- Rebiotix Inc.5 studies →Acquired
Something wrong?
Related but not counted here: Ferring Ventures Limited (affiliate).
Focus areas
Conditions Ferring Pharmaceuticals leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 254. Browse all 254 →
- Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder CancerRecruitingNCT06510374Phase 3
- A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder CancerRecruitingNCT06545955Phase 3
- Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal PelvisRecruitingNCT06668493Phase 1/2
- Study Assessing CLENPIQ as Bowel Preparation for Pediatric ColonoscopyRecruitingNCT04113382Phase 1/2
- Prospective, Multi-centre, Non-Interventional Study to Investigate the Effectiveness of REKOVELLE® for Ovarian Stimulation for Asian Women in Real World SettingsActive, not recruitingNCT06561958
- To Investigate REKOVELLE in Chinese Women Undergoing Assisted Reproductive Technologies: Effectiveness, Safety, and Patterns of Use in Real-world PracticeActive, not recruitingNCT07029451
- REKOVELLE PEN for S.C. Injection General Drug Use Survey (Controlled Ovarian Stimulation in Assisted Reproductive Technologies)CompletedNCT06545877
- Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)Active, not recruitingNCT05704244Phase 3
- A Trial to Compare Efficacy and Safety of Follitropin Delta Versus Placebo (Inactive Treatment) in the Treatment of Men With Idiopathic Infertility (Unexplained Reduction of Semen Quality) (ADAM)TerminatedNCT05403476Phase 2
- A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile InfectionCompletedNCT05831189Phase 3
- An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta at Different Time Intervals During Controlled Ovarian Stimulation.TerminatedNCT06511791Phase 1
- An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta During Controlled Ovarian StimulationTerminatedNCT06466486Phase 1
- ADSTILADRIN Early Utilization and Outcomes in the Real World SettingTerminatedNCT06026332
- A Randomised Trial Comparing the Ovarian Response of a Starting Dose of Either 10 μg or 15 μg Follitropin Delta (FE 999049) to a Starting Dose of Either 150 IU or 225 IU Follitropin Alfa (GONAL-F) in Conventional Regimens in ChinaCompletedNCT06173869Phase 3
- REBYOTA™ Prospective RegistryCompletedNCT05835219
- Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate CancerCompletedNCT00117286Phase 2/3
- NOCDURNA PASS Study Using Registries in Denmark, Germany and SwedenCompletedNCT04740645
- A Study to Measure Pharmacokinetic (PK) Concentrations of Gonadotropin-Releasing Hormone Delivered by the OmniPod PumpWithdrawnNCT07152730Phase 1
- Trial to Assess the Pattern of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation (IVF) or Intracytoplasmic Sperm Injection (ICSI) Procedures in Routine Clinical PracticeCompletedNCT05499052
- A Study of Degarelix in Taiwanese Patients With Prostate CancerCompletedNCT01220869Phase 3
- A Trial to Compare the Ovarian Response of REKOVELLE and GONAL-F in Conventional Dosing in Women Undergoing Controlled Ovarian StimulationCompletedNCT05263388Phase 3
- Post-Marketing Surveillance (PMS) Protocol of REKOVELLE Pre-Filled Pen (Follitropin Delta)CompletedNCT04654039
- Assessment of the Effectiveness of Menopur in Intrauterine InseminationCompletedNCT01354834
- Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's DiseaseCompletedNCT00740103Phase 2
- Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi SyndromeCompletedNCT01968187Phase 2
- Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Indian WomenCompletedNCT04773353Phase 3
- Specified Drug Use-results Survey (Long-term Use) on MINIRINMELT® OD Tablet (Nocturia)CompletedNCT04329975
- Investigating the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Olamkicept in Healthy Japanese PersonsCompletedNCT06515834Phase 1
- A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.WithdrawnNCT06390111Phase 4
- A Study Investigating the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Olamkicept in Healthy PersonsCompletedNCT06298032Phase 1
- A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative ColitisWithdrawnNCT06260267Phase 1
- FIRMAGON® Intensive Drug MonitoringCompletedNCT05181800
- Study to Assess Effectiveness of Therapy Timely Adjustment Based on Self-monitoring in Patients Suffering From Mild-to-moderate Ulcerative Colitis (OPTIMISE Study)CompletedNCT04340895Not applicable
- A Study to Evaluate the Effect of Carbetocin on the QT/QTc Interval in Healthy SubjectsCompletedNCT05924321Phase 1
- Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS)CompletedNCT03931941Phase 3
Sponsor listed in the registry: Rebiotix Inc. · Rebiotix Inc. — acquired company within the Ferring Pharmaceuticals group
- ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)CompletedNCT02773849Phase 3
- Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)CompletedNCT03244644Phase 3
Sponsor listed in the registry: Rebiotix Inc. · Rebiotix Inc. — acquired company within the Ferring Pharmaceuticals group
- Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND)CompletedNCT03809429Phase 3
- Prospective Evaluation of a Scoring System in Patients Newly Diagnosed With Crohn's DiseaseCompletedNCT02193048
- Compound Sodium Picosulfate Granules for Bowel Preparation in Chinese PopulationCompletedNCT04852120
- Merotocin in Mothers With Inadequate Milk Production and Infants Delivered PrematurelyTerminatedNCT02545127Phase 2
- Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-2)CompletedNCT03738618Phase 3
- Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1)CompletedNCT03740737Phase 3
- Impact of Blastocyst Morphological Development and Blastocoele Re-expansion on Pregnancy Outcome After Using REKOVELLE®TerminatedNCT03697031
- Investigation of a New Trial Drug (FE200486) in Prostate Cancer PatientsCompletedNCT00818623Phase 2
- Dose Finding Trial With a New Treatment (Degarelix) for Prostate CancerCompletedNCT00819156Phase 2
- Evaluation of Overall Compliance and Duration of Zomacton® Treatment With the Zomajet® Needle-free DeviceCompletedNCT01306357
- Extension Study of Semapimod 60 mg IV x 3 DaysCompletedNCT00741910Phase 2
- Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus PlaceboCompletedNCT00739986Phase 2
- Effectiveness and Safety of Firmagon®CompletedNCT00930319